利心Ⅰ号对实验性充血性心力衰竭大鼠血浆TNF-α及AngⅡ的影响
|
摘要
目的:探讨利心Ⅰ号对充血性心力衰竭大鼠模型血浆TNF-α及Ang-Ⅱ的影响。
方法:用腹腔注射阿霉素法复制目前公认的Wistar大鼠CHF模型。将84只动物模型随机平均分为中药对照组、西药对照组、中药低剂量组和中药高剂量组四组,进行药效学研究,并设立正常对照组和模型对照组。正常组:自由饮食、水。模型组:灌服0.9%生理盐水。西药对照组:灌服依那普利混悬液。中药对照组:灌服心宝混悬液。中药低剂量组:给予利心Ⅰ号煎剂灌胃,13.0g/kg。中药高剂量组:给予利心Ⅰ号煎剂灌胃,26.0g/kg。以上各组,每日一次,连续灌胃4周后用2%戊巴比妥钠腹腔注射麻醉,颈动脉取血,测定血浆中TNF-α和Ang-Ⅱ含量。
结果:1、模型组大鼠血浆TNF-α值明显高于正常对照组;各治疗组血浆TNF-α含量与模型组比较均明显降低,其中,中药高剂量组与西药对照组及中药低剂量组比较有显著差异;
2、模型组大鼠血浆Ang-Ⅱ含量明显高于正常对照组,各治疗组血浆Ang-Ⅱ与模型组比较均明显降低,且中药高剂量组优于中药对照组及中药低剂量组。
结论:利心Ⅰ号能够降低实验性CHF大鼠血浆TNF-α及AngⅡ水平,以中药高剂量组效果最佳。
Objective: To study the effect of LiXin Ⅰ the a-Tumor Necrosis Factor and Angiotensin Ⅱ gravity of serum of the experimental rat with Congestive Heart Failure..METHODS: Eighty four Wistar rats were selected and divided randomly into six groups :one group of them in the normal control group ;others in the model groups established by intraperitoneal injection of Adriamycin. The later was classified as follow:the control model group admonished with physiological saline ;the XinBao treatment model group admonished with XinBao mixed liquid ;the medicine treatment model group admonished with Enalapril tablet mixed liquid ;the small dose LiXin Ⅰ treatment model group admonished with Li Xin Ⅰ mixed liquid(13.0g/kg) ;the large dose LiXin I treatment group admonished with LiXin I mixed liquid(26.0g/kg). All treatment groups had continually admonished by oral gavage one time a day.food and drink were given as usual.After four weeks,blood was obtained from rat carotid artery under the aneshthesia state and TNF-α and Ang Ⅱ were tested.RESULT:The experiment results show :firstly,TNF-α of serum of rat in the control model group is higher than in the normal control group (p<0.01) . TNF-α of serum of rat in the treatment groups is lower than in the control model group(p<0.01).TNF-α in the large dose LiXin Ⅰ treatment model group is lower than in the small dose LiXin Ⅰ and medicine treatment group respectively.Di-fference between them is obvious(p<0.05). secondly , Ang Ⅱ of serum in the control model group is higher than in the normal contrst group and treatment groups .Ang Ⅱ in the large dose LiXin I treatment group is lower than in the XinBao treatment group and in the small dose LiXin treatment group respectively (p<0.01). CONCLUSION: LiXin Ⅰ can
方法:用腹腔注射阿霉素法复制目前公认的Wistar大鼠CHF模型。将84只动物模型随机平均分为中药对照组、西药对照组、中药低剂量组和中药高剂量组四组,进行药效学研究,并设立正常对照组和模型对照组。正常组:自由饮食、水。模型组:灌服0.9%生理盐水。西药对照组:灌服依那普利混悬液。中药对照组:灌服心宝混悬液。中药低剂量组:给予利心Ⅰ号煎剂灌胃,13.0g/kg。中药高剂量组:给予利心Ⅰ号煎剂灌胃,26.0g/kg。以上各组,每日一次,连续灌胃4周后用2%戊巴比妥钠腹腔注射麻醉,颈动脉取血,测定血浆中TNF-α和Ang-Ⅱ含量。
结果:1、模型组大鼠血浆TNF-α值明显高于正常对照组;各治疗组血浆TNF-α含量与模型组比较均明显降低,其中,中药高剂量组与西药对照组及中药低剂量组比较有显著差异;
2、模型组大鼠血浆Ang-Ⅱ含量明显高于正常对照组,各治疗组血浆Ang-Ⅱ与模型组比较均明显降低,且中药高剂量组优于中药对照组及中药低剂量组。
结论:利心Ⅰ号能够降低实验性CHF大鼠血浆TNF-α及AngⅡ水平,以中药高剂量组效果最佳。
Objective: To study the effect of LiXin Ⅰ the a-Tumor Necrosis Factor and Angiotensin Ⅱ gravity of serum of the experimental rat with Congestive Heart Failure..METHODS: Eighty four Wistar rats were selected and divided randomly into six groups :one group of them in the normal control group ;others in the model groups established by intraperitoneal injection of Adriamycin. The later was classified as follow:the control model group admonished with physiological saline ;the XinBao treatment model group admonished with XinBao mixed liquid ;the medicine treatment model group admonished with Enalapril tablet mixed liquid ;the small dose LiXin Ⅰ treatment model group admonished with Li Xin Ⅰ mixed liquid(13.0g/kg) ;the large dose LiXin I treatment group admonished with LiXin I mixed liquid(26.0g/kg). All treatment groups had continually admonished by oral gavage one time a day.food and drink were given as usual.After four weeks,blood was obtained from rat carotid artery under the aneshthesia state and TNF-α and Ang Ⅱ were tested.RESULT:The experiment results show :firstly,TNF-α of serum of rat in the control model group is higher than in the normal control group (p<0.01) . TNF-α of serum of rat in the treatment groups is lower than in the control model group(p<0.01).TNF-α in the large dose LiXin Ⅰ treatment model group is lower than in the small dose LiXin Ⅰ and medicine treatment group respectively.Di-fference between them is obvious(p<0.05). secondly , Ang Ⅱ of serum in the control model group is higher than in the normal contrst group and treatment groups .Ang Ⅱ in the large dose LiXin I treatment group is lower than in the XinBao treatment group and in the small dose LiXin treatment group respectively (p<0.01). CONCLUSION: LiXin Ⅰ can
引文
[1] 李南夷,邓铁涛,陈镜和.充血性心力衰竭中医病名小议[J].新中医,1994,(2):7
[2] 黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4):592-593
[3] 郭毅.试论心衰及其治疗体会[J].四川中医,1996,(8):6
[4] 董泉珍.中西医结合治疗心力衰竭的探讨[J].中国中西医结合杂志,1996,(12):745-748
[5] 成启予,等.浅谈充血性心力衰竭的中医诊断及其证治[J].南京中医学院学报,1994,(2)23-24
[6] 郝现军,等.慢性心力衰竭证治心得[J].湖北中医杂志,2002,(8):24-25
[7] 范爱平.李介鸣治疗心力衰竭的经验拾粹[J].北京中医,1995,(1):6-8
[8] 周仲瑛,等.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,2000,11(1):13
[9] 霍根红.试论充血性心力衰竭的中医病理实质[J].河南中医,1996,(5):274-276
[10] 霍根红.谈气、血、水相关理论与心力衰竭[J].河南中医药学刊,1995,(4):8-9
[11] 杜惠芳,等.慢性心力衰竭与痰之关系初探[J].河南中医药学刊,1998,(3):34-36;
[12] 王春燕.中医对充血性心力衰竭的认识及治疗对策[J].河北中医,2002,24(11):823
[13] 蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况[J].河北中医药学报,2000,15(3):41-43
[14] 杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2002,25(1):2
[15] 谢乐.中医分型治疗充血性心力衰竭77例[J].四川中医,2002,20(6):41;
[16] 成启予.浅谈充血性心力衰竭的中医诊断及其证治[J].南京中医学院学报,1994,(2):23
[17] 李南夷.邓铁涛教授治疗心衰的思路与方法[J].新中医 1995,(10):6-10
[18] 周慎,等.辩证治疗左室舒张功能不全性心力衰竭45例对比观察[J].中医杂志,1996,(11):667-669
[19] 王亚红,等.郭维琴敦授对心力衰竭的中医认识与辩治[J].河南中医,2003,(10): 10-11
[20] 申宝娜,等.袁海波教授治疗心力衰竭的经验[J].中国中医药信息杂志,2001,18(4):78
[21] 张立业,等.益气强心饮治疗充血心力衰竭88例临床观察[J].中医杂志,1994,35(1):31
[22] 杨蕊琳.病、证结合论治充血性心力衰竭[J].贵阳中医学院学报,2000,22(4):36
[23] 冯国标.略论慢性心衰的辩证论治[J].河南中医药学刊 1998,13(2):6
[24] 顾炳岐.救心方治疗慢性心力衰竭34例[J].中医药研究,1999,15(2):56
[25] 胡元会,等.中药心复康治疗气虚血瘀型充血心力衰竭33例疗效观察[J].浙江中医学院学报,2002,24(2):39
[26] 李秋风,等.强心乐治疗慢性充血性心力衰竭的临床研究[J].中医研究,1998,11(3):11
[27] 吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究[J].山东中医杂志 2001,20(12):715
[28] Kannel WB. Epidemiology and prevention of cardiac failure: Framinhan study insights. Ear Heart J, 1987; 8 suppl F: 23-6
[29] 王士雯,等.老年心力衰竭的流行病学、病因学及发病诱因[J].实用老年医学,1997.11(3):97
[30] 张艳.强心通脉汤治疗慢性充血性CHF[J].辽宁中医杂志,1998,25(4):168
[31] Katz Am. Regression of left ventricular hypertrophy: New hopr for dying hearts [J]. Circulation, 1998; 98: 623-624
[32] Cruiokshank J M, Neil-DwyerG, DegouteJ P, et al[J]. lancet, 1987, 2: 585-589
[33] Ara: H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor[J] Nature 1990, 348(6303): 730-732
[34] Pernow J et al. Ciroulation, 1996, 28: 2077-2082
[35] Renz H Gong JH, Schmidt A et al. J Immunal, 1998; 141(7): 2388
[36] Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonist in heart failure [J]. Cardiovasc pharmacol, 2000, 35(4 suppl2): 569-573
[37] Aukrust P, UelandT, Lien E et al. Am J Cardiol, 1999, 83: 376-382
[38] 苏国海,等.肿瘤坏死因子、白介素-1在充血性心力衰竭发生发展中的作用[J].山东医药,1999,39(6):10
[39] 邱飞.肿瘤坏死因子α与心力衰竭的研究进展[J].国外医学药学分册,2003,30(6):326-328
[40] 戴闺柱.心力衰竭病理生理概念的治疗学意义[J].中华心血管病杂志,1995,23(2):147
[41] 胡厚祥.心力衰竭对心肌细胞凋亡的研究进展[J].国外医学(心血管疾病分册),1998,25(1):10
[42] Castagnino HE, Toranzos FA, Milei J, et al.[J] Int J Cardiol, 1992, 35: 101-114
[43] 胡高频.细胞凋亡和充血性心力衰竭.心血管病学进展,1999,20(5):282-284
[44] Colucci ws. Apoptosis in the heart [J]. N Engl J Med. 1996, 335: 1224-1226
[45] Ericm, Renee VC, Yinsit J, et al. [J] circulation Res, 1993, 72: 57-64
[46] Halazonetis YD. Georgopoulosk, Greenborg ME.[J]. Cell, 1988, 55: 917-924
[47] 芮磊,等.充血性心力衰竭患者血浆一氧化氮合一氧化氮合酶的改变[J].现代中西医结合杂志,2002,11(8):683-684
[48] angenickel T, Pagel I, Hohnel K, et al. Differential requlation of Cordinc ANP and BNPmRNA in defferent stage of experinoental heart failure.[J] Am I phyniol heart phyaiol. 2000, 278: 1500-1506
[49] Richard MJ, et al.[J] Biochem Biophys Res Commun. 1988, 153: 1257
[50] 王志坚,赵水平.L-精氨酶对心力衰竭患者血管内皮功能的影响[J].中国循环杂志,2003,18(2):135-137
[51] French BA. Cardial Rev, 1997, 5: 129-140
[52] Komatsn S, Panes J, Russell JM. Et al. Effects of chronic arterial Hypertension on constitutive and induced intercellular adhesion molocule-1 expression in vivo. Hypertersion. 1997, 29: 683-689
[53] 王晓明,等.培哚普利对充血性心力衰竭患者血浆细胞粘附因子-1的影响[J].临床心血管杂志,2002,18(2):51—53
[54] 张均田,等.人参皂甙Rb_1和Rg_1对小鼠中枢神经递质受体和脑内蛋白质合成的影响[J].药学学报 1988;23(1):12
[55] 张均田.中国药理通讯 1989;6(3):4
[2] 黄平东.中医古籍对心力衰竭的论述探要[J].中医药学刊,2003,21(4):592-593
[3] 郭毅.试论心衰及其治疗体会[J].四川中医,1996,(8):6
[4] 董泉珍.中西医结合治疗心力衰竭的探讨[J].中国中西医结合杂志,1996,(12):745-748
[5] 成启予,等.浅谈充血性心力衰竭的中医诊断及其证治[J].南京中医学院学报,1994,(2)23-24
[6] 郝现军,等.慢性心力衰竭证治心得[J].湖北中医杂志,2002,(8):24-25
[7] 范爱平.李介鸣治疗心力衰竭的经验拾粹[J].北京中医,1995,(1):6-8
[8] 周仲瑛,等.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究[J].南京中医药大学学报,2000,11(1):13
[9] 霍根红.试论充血性心力衰竭的中医病理实质[J].河南中医,1996,(5):274-276
[10] 霍根红.谈气、血、水相关理论与心力衰竭[J].河南中医药学刊,1995,(4):8-9
[11] 杜惠芳,等.慢性心力衰竭与痰之关系初探[J].河南中医药学刊,1998,(3):34-36;
[12] 王春燕.中医对充血性心力衰竭的认识及治疗对策[J].河北中医,2002,24(11):823
[13] 蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况[J].河北中医药学报,2000,15(3):41-43
[14] 杨培君,杨磊.充血性心力衰竭的中医证治概要[J].陕西中医学院学报,2002,25(1):2
[15] 谢乐.中医分型治疗充血性心力衰竭77例[J].四川中医,2002,20(6):41;
[16] 成启予.浅谈充血性心力衰竭的中医诊断及其证治[J].南京中医学院学报,1994,(2):23
[17] 李南夷.邓铁涛教授治疗心衰的思路与方法[J].新中医 1995,(10):6-10
[18] 周慎,等.辩证治疗左室舒张功能不全性心力衰竭45例对比观察[J].中医杂志,1996,(11):667-669
[19] 王亚红,等.郭维琴敦授对心力衰竭的中医认识与辩治[J].河南中医,2003,(10): 10-11
[20] 申宝娜,等.袁海波教授治疗心力衰竭的经验[J].中国中医药信息杂志,2001,18(4):78
[21] 张立业,等.益气强心饮治疗充血心力衰竭88例临床观察[J].中医杂志,1994,35(1):31
[22] 杨蕊琳.病、证结合论治充血性心力衰竭[J].贵阳中医学院学报,2000,22(4):36
[23] 冯国标.略论慢性心衰的辩证论治[J].河南中医药学刊 1998,13(2):6
[24] 顾炳岐.救心方治疗慢性心力衰竭34例[J].中医药研究,1999,15(2):56
[25] 胡元会,等.中药心复康治疗气虚血瘀型充血心力衰竭33例疗效观察[J].浙江中医学院学报,2002,24(2):39
[26] 李秋风,等.强心乐治疗慢性充血性心力衰竭的临床研究[J].中医研究,1998,11(3):11
[27] 吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究[J].山东中医杂志 2001,20(12):715
[28] Kannel WB. Epidemiology and prevention of cardiac failure: Framinhan study insights. Ear Heart J, 1987; 8 suppl F: 23-6
[29] 王士雯,等.老年心力衰竭的流行病学、病因学及发病诱因[J].实用老年医学,1997.11(3):97
[30] 张艳.强心通脉汤治疗慢性充血性CHF[J].辽宁中医杂志,1998,25(4):168
[31] Katz Am. Regression of left ventricular hypertrophy: New hopr for dying hearts [J]. Circulation, 1998; 98: 623-624
[32] Cruiokshank J M, Neil-DwyerG, DegouteJ P, et al[J]. lancet, 1987, 2: 585-589
[33] Ara: H, Hori S, Aramori I, et al. Cloning and expression of a cDNA encoding an endothelin receptor[J] Nature 1990, 348(6303): 730-732
[34] Pernow J et al. Ciroulation, 1996, 28: 2077-2082
[35] Renz H Gong JH, Schmidt A et al. J Immunal, 1998; 141(7): 2388
[36] Sutsch G, Kiowski W. Endothelin and endothelin receptor antagonist in heart failure [J]. Cardiovasc pharmacol, 2000, 35(4 suppl2): 569-573
[37] Aukrust P, UelandT, Lien E et al. Am J Cardiol, 1999, 83: 376-382
[38] 苏国海,等.肿瘤坏死因子、白介素-1在充血性心力衰竭发生发展中的作用[J].山东医药,1999,39(6):10
[39] 邱飞.肿瘤坏死因子α与心力衰竭的研究进展[J].国外医学药学分册,2003,30(6):326-328
[40] 戴闺柱.心力衰竭病理生理概念的治疗学意义[J].中华心血管病杂志,1995,23(2):147
[41] 胡厚祥.心力衰竭对心肌细胞凋亡的研究进展[J].国外医学(心血管疾病分册),1998,25(1):10
[42] Castagnino HE, Toranzos FA, Milei J, et al.[J] Int J Cardiol, 1992, 35: 101-114
[43] 胡高频.细胞凋亡和充血性心力衰竭.心血管病学进展,1999,20(5):282-284
[44] Colucci ws. Apoptosis in the heart [J]. N Engl J Med. 1996, 335: 1224-1226
[45] Ericm, Renee VC, Yinsit J, et al. [J] circulation Res, 1993, 72: 57-64
[46] Halazonetis YD. Georgopoulosk, Greenborg ME.[J]. Cell, 1988, 55: 917-924
[47] 芮磊,等.充血性心力衰竭患者血浆一氧化氮合一氧化氮合酶的改变[J].现代中西医结合杂志,2002,11(8):683-684
[48] angenickel T, Pagel I, Hohnel K, et al. Differential requlation of Cordinc ANP and BNPmRNA in defferent stage of experinoental heart failure.[J] Am I phyniol heart phyaiol. 2000, 278: 1500-1506
[49] Richard MJ, et al.[J] Biochem Biophys Res Commun. 1988, 153: 1257
[50] 王志坚,赵水平.L-精氨酶对心力衰竭患者血管内皮功能的影响[J].中国循环杂志,2003,18(2):135-137
[51] French BA. Cardial Rev, 1997, 5: 129-140
[52] Komatsn S, Panes J, Russell JM. Et al. Effects of chronic arterial Hypertension on constitutive and induced intercellular adhesion molocule-1 expression in vivo. Hypertersion. 1997, 29: 683-689
[53] 王晓明,等.培哚普利对充血性心力衰竭患者血浆细胞粘附因子-1的影响[J].临床心血管杂志,2002,18(2):51—53
[54] 张均田,等.人参皂甙Rb_1和Rg_1对小鼠中枢神经递质受体和脑内蛋白质合成的影响[J].药学学报 1988;23(1):12
[55] 张均田.中国药理通讯 1989;6(3):4